knowledge -WSS

knowledge

author：knowledge 2025-10-02 18:46:30 - browse：59

Sen. Rand Paul (C) (R-KY) questions Homeland Security Secretary Alejandro Mayorkas and FBI Director Christopher Wray during a hearing held by the Senate Homeland Security and Governmental Affairs Committee October 31, 2023 in Washington, DC. — Sen. Rand Paul (R-Ky.) Win McNamee/Getty Images

WASHINGTON — A Senate panel Wednesday passed a bill aimed at preventing certain Chinese companies from doing business in the United States. The sole no vote was by Sen. Rand Paul (R-Ky.), who worries that Congress is using anger toward China as a cover for advancing parochial interests.

Many in Congress are worried the Chinese government and military are using the rising dominance of national companies to gather Americans’ genetic information, which could be used for reasons that range from creating bioweapons to giving China a leg up in drug development.

The Biosecure Act, by Homeland Security and Governmental Affairs Chair Gary Peters (D-Mich.), is a response to those concerns. The bill would block the U.S. government from contracting with companies that do business with Chinese “biotechnology companies of concern,” and it names four companies that must be on that list: BGI Genomics, MGI, Complete Genomics, WuXi AppTec, and any subsidiary, parent affiliate, or successor of these companies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Listen: Biogen's messy board & Laronde's data problem

WSS

Ultragenyx gene therapy for rare liver ailment succeeds in late

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

HIV drugs protect against transmission, even in unprotected sex

Duchenne patients, backed by ‘dark money’ group, to debate drug prices

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Did the public have the right to know Arthur Ashe had AIDS?

focus

knowledge

knowledge

Medical leaders decry Supreme Court decision on affirmative action

Pfizer's Covid pill remains 89% effective in final analysis, company says

ChatGPT in medicine: STAT answers readers' burning questions

Innovation in antibiotics is ailing. 'Brain drain' may kill it

Medical leaders decry Supreme Court decision on affirmative action

Innovation in antibiotics is ailing. 'Brain drain' may kill it

Cancer drug shortages should be causing more outrage

Pfizer's Covid pill remains 89% effective in final analysis, company says

23andMe had bad news about my health. I wish a person had delivered it

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

explore

Inside the fall of star MIT scientist David Sabatini

NIH documents show early flaws of $1.6 billion long Covid program

Ultragenyx gene therapy for rare liver ailment succeeds in late

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Shifting the focus from loneliness to social health

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

entertainment

entertainment

knowledge

focus